WHO, ITU to expand use of AI globally

The International Telecommunication Union (ITU) and World Health Organization (WHO) are converging for the global expansion of the use of artificial intelligence (AI) “to advance health for all worldwide.”

Both organizations will work through the ITU Focus Group on AI for Health and spearhead a two-year analysis to identify additional “AI in healthcare” use cases and develop a standardized framework to use AI on a global scale.

"The health sector is in many countries among the largest economic sectors or one of the fastest-growing, signaling a particularly timely need for international standardization of the convergence of AI and health,” said Thomas Wiegand, ITU Focus Group on AI for Health Chairman in a prepared statement issued by the ITU.

The group will also work with researchers, practitioners and policy-makers to develop policies to ensure the safe and appropriate use of AI in health. They will also identify data for training AI algorithms, providing a more uniform approach across the globe.

"AI could help patients to assess their symptoms, enable medical professionals in underserved areas to focus on critical cases, and save great numbers of lives in emergencies by delivering medical diagnoses to hospitals before patients arrive to be treated," said ITU Secretary-General Houlin Zhao in a prepared statement. "ITU and WHO plan to ensure that such capabilities are available worldwide for the benefit of everyone, everywhere."

""

As a senior news writer for TriMed, Subrata covers cardiology, clinical innovation and healthcare business. She has a master’s degree in communication management and 12 years of experience in journalism and public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.